Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
CHOLOVUE is an injectable diagnostic agent developed by Bracco, approved in 1981 for diagnostic imaging purposes. The specific indication and mechanism of action are not publicly detailed in available data, but the injectable formulation suggests use in imaging or visualization procedures. As a legacy diagnostic product, it represents a mature category within pharmaceutical imaging.
As a legacy diagnostic injectable approaching loss of exclusivity with low commercial pressure (30/100), this product likely operates with a small, maintenance-focused brand team focused on sustaining revenue rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on CHOLOVUE offers stable, maintenance-focused career experience in a mature diagnostic category, but limited growth and innovation exposure. This role is best suited for professionals seeking operational excellence in a legacy product or those transitioning into other therapeutic areas.
Worked on CHOLOVUE at Bracco? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.